<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334633</url>
  </required_header>
  <id_info>
    <org_study_id>F040329003</org_study_id>
    <secondary_id>R01AI058033</secondary_id>
    <nct_id>NCT00334633</nct_id>
  </id_info>
  <brief_title>Treatment of Bacterial Vaginosis (BV) With Tinidazole</brief_title>
  <official_title>Tinidazole for the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <brief_summary>
    <textblock>
      We are trying to determine if treatment of bacterial vaginosis with tinidazole is better than
      treatment with metronidazole
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the
      U.S. and has been associated with complications including preterm delivery of infants, pelvic
      inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of
      sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV). Control of
      BV has been advocated as a means of decreasing the prevalence of these complications.
      However, the etiology of BV remains unknown and the current treatment regimens are inadequate
      in terms of initial cure and recurrence rates. Although not currently licensed in the U.S.,
      tinidazole is an antimicrobial related to metronidazole which has shown promise for the
      treatment of BV in European studies and is widely used worldwide for the treatment of
      trichomoniasis including infections which are resistant to metronidazole. We hypothesize that
      qualities of tinidazole such as its longer half-life and its seemingly superior side effect
      profile as compared to oral metronidazole will result in its being a more efficacious drug
      for the treatment of BV than the currently available options.

      The specific aims of this project are:

        1. To compare the efficacy of two different doses of tinidazole with oral metronidazole for
           the initial treatment of symptomatic BV as well as short-term recurrence rates

        2. To compare the side effect profiles of tinidazole versus metronidazole in the treatment
           of BV

        3. To compare drug levels of tinidazole and metronidazole in the vaginal secretions and
           correlate with microbiologic cure of BV as well as rates of recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure of Bacterial Vaginosis</measure>
    <time_frame>one month</time_frame>
    <description>resolution of Amsel criteria for bacterial vaginosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>baseline to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">593</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metronidazole 500 BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tinidazole 500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinidazole 500 BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tinidazole 1 gm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinidazole 1 gm BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinidazole, metronidazole</intervention_name>
    <description>Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>tinidazole 500</arm_group_label>
    <arm_group_label>tinidazole 1 gm</arm_group_label>
    <other_name>Tindamax, Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women be at least 18 years of age

          -  Have symptoms of vaginal odor and or/discharge

          -  Meet the clinical (Amsel) criteria for BV

          -  Willing to participate in research

        Exclusion Criteria:

          -  Presence of another vaginal infection or STD

          -  Allergy to metronidazole

          -  Pregnant or nursing

          -  Use of oral or intravaginal antibiotics within the past 2 weeks

          -  HIV or other chronic disease

          -  Inability to keep return appointments
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Schwebke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson County Department of Health STD Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <results_first_submitted>March 3, 2011</results_first_submitted>
  <results_first_submitted_qc>May 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2011</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jane Schwebke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>tinidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>women attending a sexually transmitted disease (STD) clinic with symptomatic bacterial vaginosis (BV)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metronidazole</title>
          <description>metronidazole 500 twice a day (BID) for 7 days; 197 participants</description>
        </group>
        <group group_id="P2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="P3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metronidazole</title>
          <description>metronidazole 500 BID for 7 days; 197 participants</description>
        </group>
        <group group_id="B2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="B3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="197"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="196"/>
            <count group_id="B4" value="593"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6.2"/>
                    <measurement group_id="B2" value="28.3" spread="6.6"/>
                    <measurement group_id="B3" value="28.5" spread="6.8"/>
                    <measurement group_id="B4" value="28.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure of Bacterial Vaginosis</title>
        <description>resolution of Amsel criteria for bacterial vaginosis</description>
        <time_frame>one month</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>metronidazole 500 BID for 7 days; 197 participants</description>
          </group>
          <group group_id="O2">
            <title>Tinidazole 500 mg</title>
            <description>tinidazole 500 BID for 7 days; 200 particpants</description>
          </group>
          <group group_id="O3">
            <title>Tinidazole 1 gm</title>
            <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
          </group>
        </group_list>
        <measure>
          <title>Cure of Bacterial Vaginosis</title>
          <description>resolution of Amsel criteria for bacterial vaginosis</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of BV</title>
        <time_frame>baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>metronidazole 500 BID for 7 days
tinidazole, metronidazole: Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid</description>
          </group>
          <group group_id="O2">
            <title>Tinidazole 500</title>
            <description>tinidazole 500 BID for 7 days
tinidazole, metronidazole: Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid</description>
          </group>
          <group group_id="O3">
            <title>Tinidazole 1 gm</title>
            <description>tinidazole 1 gm BID for 7 days
tinidazole, metronidazole: Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of BV</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metronidazole</title>
          <description>metronidazole 500 BID for 7 days; 197 participants</description>
        </group>
        <group group_id="E2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="E3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="126"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="161"/>
                <counts group_id="E3" events="91" subjects_affected="91" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>vaginal candidiasis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="126"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="161"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>jane R Schwebke, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-5665</phone>
      <email>schwebke@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

